AAD 2026 — Atopic Dermatitis·Psoriasis Pipeline Expansion. JAK·IL-23·GLP-1 Combination System Treatment Era
Skin treatment no longer sees only skin. AAD 2026 (3.26~31 Denver) = atopic·psoriasis pipeline JAK·IL-23·GLP-1 combination expansion to system treatment. Beyond L66 nemolizumab 24-week, age expansion + mechanism diversification + cardiometabolic combination.
Key Announcement
AAD 2026 Denver 2026.3.26~31, atopic·psoriasis·acne·aging·cancer pipelines.
1. Nemolizumab Pediatric Expansion
L66 nemolizumab + L74 pediatric data: IL-31Rα blockade, pediatric 2~11 years 16-week EASI75 ~70%, 52-week EASI90 60~70%, good safety
Meaning: Pediatric atopic + prurigo nodularis simultaneous indication, pruritus-dominant priority, L63 nemolizumab 24-week → L74 pediatric expansion
2. Psoriasis - 3 Biologic-Level Oral Drugs
icotrokinra (J&J): Oral IL-23 receptor block, biologic-level efficacy, once daily
zasocitinib (Takeda): Oral TYK2 block, psoriasis + autoimmune, once daily
envudeucitinib (Pfizer/Innovaderm): Oral TYK2/JAK1 dual, once daily
Meaning: Biologic injection alternative, oral = ↑ convenience, daily entry
3. Psoriasis + Obesity — Ixekizumab + Tirzepatide
Ixekizumab: IL-17A biologic, primary target
Tirzepatide: GLP-1·GIP dual (L66·L72), weight·diabetes
Combo effect (AAD 2026): Psoriasis improvement + cardiometabolic effects, weight·glucose·BP simultaneous, system treatment = skin + obesity + diabetes
L74 Dimension - 2nd Axis
40 pillars + L66 GLP-1 + L74 AAD combination: L63 nemolizumab 24-week, L66 ASCO GLP-1 breast cancer prevention, L66 Auvelity·Leqembi (neuro), L74 AAD 2026 (skin system treatment) = skin → system treatment expansion.
Korean Implications
Korean atopic·psoriasis: Nemolizumab MFDS (2024), partial insurance, psoriasis biologics (Stelara·Skyrizi·Tremfya·Cosentyx·Taltz), oral JAK (Olumiant·Rinvoq)
AAD 2026 drug adoption: icotrokinra 20272028 expected, zasocitinib·envudeucitinib 2028, Ixekizumab + Tirzepatide combo standardization progressing
Daily Guide
Atopic (adult): Basic moisturizing·irritant avoid, drug topical (TCS·TCI·Eucrisa) → biologic (Dupixent·nemolizumab), perimenopausal worsening possible
Psoriasis (women): Basic moisturizing·UV, drug topical → phototherapy → biologic·oral, comorbid obesity·cardiometabolic eval (L74 core)
Autoimmune integrated care: Autoimmune + obesity·diabetes comprehensive eval, L66 GLP-1 + L74 IL-17 combination possibility, OB-GYN + dermatology collaboration
FAQ
Q. Pediatric atopic drug from 2 years? A. L74 nemolizumab data = 2~11 indication. Doctor evaluation. Basic moisturizing·irritant avoid first.
Q. Oral psoriasis drug vs injection? A. Similar or superior efficacy (AAD 2026). Oral convenience ↑. Some prefer injection. Doctor decision.
Q. Psoriasis + obesity simultaneous drug? A. AAD 2026 Ixekizumab + Tirzepatide combo data. Skin + weight·diabetes. Doctor decision.
Q. Korean AAD drugs when? A. icotrokinra·zasocitinib 2027~2028. Ixekizumab + Tirzepatide combo standardization progressing.
Conclusion
AAD 2026 = skin treatment system combination era. Nemolizumab pediatric expansion + psoriasis 3 oral drugs + Ixekizumab + Tirzepatide combination. L74 = 55 pillars + expansion·global·policy dimension (skin system combination 2nd axis). Korea 2027~2028 adoption. Skin = system signal.